ApoE Peptides Inhibit Hepatitis C Virus Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection, such as combination therapy with pegylated interferon and ribavirin, have limited efficacy and severe side effects, necessitating the development of new antiviral drugs that can effectively inhibit HCV entry into cells.
Innovation Solution
Development of novel apolipoprotein E (apoE) peptides that inhibit HCV binding to cell surfaces by competing with viral particles for cellular receptors, specifically designed to include a receptor binding fragment and lipid binding capabilities, with some forms incorporating an N-terminal cysteine for dimerization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with pegylated interferon and ribavirin is used to treat HCV infection, then antiviral efficacy is achieved in 40-80% of patients, but severe side effects occur resulting in poor patient compliance
Solution Approach 1:
The patent extracts and utilizes the functional domain of apolipoprotein E (amino acids 1-165) that is responsible for receptor binding and HCV entry mediation. By isolating this specific functional segment and engineering it into stabilized polypeptide variants with enhanced half-life, the invention achieves antiviral activity without the toxic effects of interferon-based therapies
Solution Approach 2:
The stabilized apoE polypeptides act as decoy intermediaries that bind to HCV particles and block their entry into hepatocytes. These engineered polypeptides serve as mediator molecules that intercept the virus-receptor interaction, preventing infection without triggering the severe immune responses associated with interferon therapy
2Reliability
If new antiviral drugs are developed to treat HCV infection, then therapeutic effectiveness can be improved, but drug development complexity and time increase
Solution Approach 1:
The invention segments the full-length apolipoprotein E into its functional domain (amino acids 1-165) responsible for HCV entry mediation. This segmentation allows creation of smaller, more manageable polypeptide variants that can be engineered for stability while maintaining therapeutic activity, simplifying the drug development process
Solution Approach 2:
The patent applies parameter changes by introducing specific stabilizing mutations (e.g., disulfide bridges, proline substitutions) into the apoE polypeptide sequence. These parameter modifications enhance the half-life and stability of the therapeutic agent without requiring complete redesign of the molecule, accelerating development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The apoE peptides effectively block HCV entry into hepatocytes with minimal cytotoxicity, demonstrating potent inhibition of HCV infection while maintaining stability and activity over time, suggesting a direct role of apoE in mediating HCV entry and providing a potential therapeutic approach for HCV treatment.
Implementation Method 1
apolipoprotein E (apoE), appears to be assembled into infectious virions and plays a crucial role in conferring virus infectivity... The 299-residue apoE is a main component of lipoproteins in plasma and participates in lipid transport via its ability to bind to multiple cell surface receptors
Implementation Method 2
The polypeptides include an N-terminal cysteine, and can form dimers
Data Source
AI summary
Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods.